A Double-Blind, Randomized Study to Compare Onabutuliumtoxin A Versus Kenalog for Intravaginal Trigger Point Injections in the Treatment of Chronic Pelvic Pain

Trial Profile

A Double-Blind, Randomized Study to Compare Onabutuliumtoxin A Versus Kenalog for Intravaginal Trigger Point Injections in the Treatment of Chronic Pelvic Pain

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 03 Apr 2018

At a glance

  • Drugs Botulinum-Toxin-A (Primary) ; Triamcinolone
  • Indications Pelvic pain
  • Focus Therapeutic Use
  • Most Recent Events

    • 27 Mar 2018 Planned End Date changed from 1 May 2018 to 1 Jul 2018.
    • 27 Mar 2018 Planned primary completion date changed from 1 Feb 2018 to 1 Apr 2018.
    • 27 Mar 2018 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top